BioCentury
ARTICLE | Emerging Company Profile

Recalcitrant Targets

How Kronos’ small molecule microarrays could help drug the undruggable

September 20, 2018 7:37 PM UTC

With a fresh take on small molecule microarray technology, Kronos Bio Inc. aims to identify small molecule inhibitors of oncology targets considered undruggable, starting with a splice variant of the androgen receptor expressed in metastatic castration-resistant prostate cancer.

The biotech’s platform attracted former Gilead Sciences Inc. EVP of R&D and CSO Norbert Bischofberger, who joined Kronos as president and CEO in May, the same month the company announced it raised $18 million in seed funding. ...